<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02295085</url>
  </required_header>
  <id_info>
    <org_study_id>UC2012-3745</org_study_id>
    <secondary_id>P30ES006096</secondary_id>
    <nct_id>NCT02295085</nct_id>
  </id_info>
  <brief_title>Fernald Community Cohort -18 Year Observational Study</brief_title>
  <acronym>FCC</acronym>
  <official_title>Fernald Community Cohort - 18 Year Observational Study With Bio Banked Blood and Urine Samples</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Environmental Health Sciences (NIEHS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Fernald Community Cohort consists of the 9782 persons who were enrolled in the Fernald
      Medical Monitoring Program (FMMP) (1990-2008). The initial comprehensive examination
      conducted as part of the Fernald Medical Monitoring Program (FMMP) began in the autumn of
      1990. The FMMP provided 9,782 initial examinations and 42,775 re-examinations. An extensive
      computerized database and biospecimen repository was created to provide research resources
      for future studies. All questionnaire, examination and diagnostic procedure data collected
      from the FMMP were [coded by certified medical record coders,] double entered with
      verification into a SAS database on site of the examinations. Cryo-preserved blood and urine
      samples were collected at enrollment and at various intervals throughout follow-up. At the
      first examination three 1-ml aliquots of whole blood, plasma, serum, urine and urine with
      buffer were obtained from each participant (15 aliquots per person) for future analyses.
      Additional whole blood and serum was obtained in 1996-1997 and 2006-2008. Specimens have been
      stored in -80 degree freezers; over 160,000 biospecimens are in the archive. Since 1994, the
      FCC has had an established procedure for sharing data and biospecimens with qualified
      researchers. Both the policy and application forms can be found at
      www.eh.uc.edu/fmmp/research.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Fernald Medical Monitoring Program (FMMP) was designed to provide a comprehensive
      evaluation of current health and risks for future disease and collect information for
      subsequent research studies for those who met the enrollment criteria in the FMMP.

      Purpose of the FMMP

        1. To provide a complete evaluation of current health.

        2. To provide a comprehensive evaluation of risk factors for disease, which may develop in
           the future.

        3. To educate on how to reduce the chances of developing disease in the future.

        4. Create an epidemiologic database for future studies.

      Procedures

        1. Consent to participate-The first step in the process was to verbally explain to
           potential participants the components of the program, the results they would receive,
           the future use of data and biospecimens. Staff then witnessed their signature on the
           consent form.

        2. Questionnaire- Complete an extensive health questionnaire that was administered each
           year. Data collected included personal characteristics (age, sex, current address,
           income, education, marital status, other persons in the home), current and past
           occupations, family medical history, past addresses and dates. SF-36 (and later the
           SF-12) health status questionnaire was administered and questions on current diet were
           asked.

        3. History and Physical Examination by physician- A board Certified Physician in Internal
           Medicine, Occupational Medicine, or Family Practice performed a comprehensive Review of
           Systems and Physical examination.

        4. Laboratory Testing- Blood samples were obtained for a series of screening tests which
           include complete blood count with differential, blood sugar, thyroid function tests,
           chemistry liver, kidney and cholesterol profiles. Men age 49-79 were offered a PSA
           (prostate specific antigen) each year. Urine was collected for urinalysis (occult and
           microscopic) and a beta2 microglobulin, urine creatine, protein, and microalbumin was
           completed at the first examination, All Laboratory test results are housed in a SAS
           database.

        5. X-ray Examination- All adults were offered a baseline chest x-ray and offered again at
           the third through seventh examination cycles. Chest x-ray was offered annually for those
           with abnormalities. Women 40 years of age or over were offered a screening mammogram
           each year. The complete narrative of the reports of these procedures has been entered
           into the SAS database. Findings and recommendations have been coded.

        6. Other testing - All adults were offered a baseline electrocardiogram (EKG) and a
           baseline PFT (pulmonary function test). Those who were age 45 were tested for occult
           blood in their stool at each examination.

        7. Blood and urine samples for research- Blood and urine samples were collected and
           processed into 15 aliquots (3 whole blood, 3 plasma, 3 serum 3 urine, 3 buffered urine)
           and frozen in -80 freezers to be used for future epidemiologic studies.

      Follow up

      At the conclusion of the examination physicians recorded any new medical diagnoses apparent
      at the time of the examination, as well as diagnostic uncertainties requiring further
      diagnostic testing. Nurses conducted participant follow up by phone for at least six months
      on all those needing further testing or treatment by their usual primary care practitioner.
      New diagnoses recognized through this follow up also are recorded on the medical record.
      Outside medical records (usually a pathology report) are obtained to validate any new
      diagnosis of cancer. This same procedure was used at the time of the periodic medical
      examination offered every three years until 1999. and then every two years until 2008.

      Ongoing Questionnaires

      Following the initial questionnaire, participants also are asked to complete yearly
      questionnaire requesting information about new medical problems and recent hospitalizations
      and surgeries, and 77,638 completed questionnaire from adults have been received by the
      program. Yearly questionnaire return rates varied by Program year, but in 2008 were 44.8% of
      the original enrollees. Yearly questionnaire were computer-generated so that participants who
      missed a past questionnaire are re-issued critical data items from those missed
      questionnaires, greatly improving total ascertainment on any data item. Continued
      participation in the program at the time of re-examination fell 23% at the first re-exam for
      adults and remained at about 50% for each examination since then. (Some participants skip one
      exam but then return for the next one.) Only 216 participants have withdrawn from the Program
      and are no longer contacted or followed (except to obtain information when we learn of their
      death); 184 participants are lost to follow-up. Thus, over 50% of initial participants
      continued to get semi-annual examinations and we know the location and vital status of 97% of
      the initial participants.

      Follow up time, considering the period under observation to be from the first examination
      date until the last questionnaire or exam contact, or death, was most program participants,
      we have 12.5 years of follow-up. Death certificates have been obtained, or an NDI search
      completed, on most of the 662 participants who have died.

      Background of the Fernald Medical Monitoring Program

      The Fernald Medical Monitoring Program (FMMP) provided health screenings and health promotion
      service as the result of a settlement between the US Department of Energy (DOE) and attorneys
      representing individuals (class members) living or working within five miles of the Feeds
      Material Processing Center (FMPC), a uranium processing plant in Fernald, Ohio. The lawsuit
      was based on emotional distress related primarily to the potential for harmful health effects
      resulting from environmental releases. The settlement also included provisions for supporting
      epidemiological studies.

      This cohort is appropriate to use for studies that are not related to radiation or uranium
      exposure. Much of the cohort never received uranium exposure beyond the background exposure
      received by the general population. Extensive uranium dose reconstruction using methods
      developed by the CDC demonstrate that over 60% of the cohort had such minimal exposure to
      uranium and radon that their cumulative ionizing radiation exposure was less that 3.2% over
      lifetime background levels. For the US population, background ionizing radiation exposure is
      estimated to be 3.6 mSv per year or 288 mSv lifetime (80 Years), but the range of individual
      exposure estimates is wide, depending primarily on geographic location (1-10 mSv per year).
      The maximum estimate of yearly exposure beyond background for this 60% sub-cohort is only 5.5
      mSv, very small compared to the yearly individual dose variation. Lifetime cumulative
      exposure from the FMPC for this unexposed sub-group ranges from 0.0 to 0.45 Sv. For the other
      40% of the cohort, cumulative lifetime exposure from FMPC ranges (approximately) from 450 mSv
      (0.45 SV) to 3660 mSv (3.66 Sv).

      On January 13, 2013 the Special Master of the Fernald Settlement Fund entered into an
      agreement to transfer the FMMP database and biospecimen collection to the University of
      Cincinnati for the purpose of maintaining the database and biospecimen collection for use in
      epidemiological and genetic research. The Fernald Medical Monitoring Program (FMMP) became
      the Fernald Community Cohort (FCC).

      Strengths of this Program for research

      All diagnoses have been assigned ICD-9 codes by a certified medical record coder. All
      medication information is coded by type of drug using a 4-digit code. The extensive coding of
      the medical information of this large cohort provides the immediate opportunity to ask
      specific research questions. For example, all of the 28,518 mammogram reports and the 27,855
      chest x-ray reports in the database have been literally coded (coding of phrases) using a
      list of over 200 3-digit codes, specific to each type of imaging. Exposure or risk factor
      metrics have been developed from questionnaire information, and are available in the
      database. For example, we have developed matrix of cumulative cigarette pack-years for all
      participants, for each year after their year of program enrollment. We also have matrices for
      family history of each type of cancer for each program participant with number of first
      degree and total number of blood relatives with that type of cancer.

      We have collected family structure information from all participants on several different
      occasions and through several types of questions (family history at the time of the initial
      examination, questions about who else lived with you, and questions about offspring on one of
      the yearly questionnaires).

      In each instance, we have recorded names of these relatives and coded each mentioned family
      member with their FMMP ID, if they are program participants. With each questionnaire we also
      ask participants of the names of three personal contacts, and record their relationship to
      the program participants. The FMMP database contains the information needed to create family
      pedigrees, and note which family members are Program participants.

      The extensive information on participants of the FMMP allows for the selection of tailored
      control groups. Criteria for controls for studies may differ depending on the disease and the
      lifestyle factor being studied. For example, the FMMP has provided Dr. Marshall Anderson with
      a set of controls for studies of identified susceptibility genetic variants related to
      cigarette smoking and lung cancer. For this study, the controls were persons with no first
      degree relatives with lung cancer, age &gt; 60 years, and with a &gt; 20 pack year cigarette
      smoking history. Our large cohort and extensive database enabled us to identify more than the
      needed 200 controls from the group without environmental uranium exposure. We will be
      conducting a similar control selection for Dr. Daniel Nebert, searching for &quot;highly
      resistant&quot; persons for his study of susceptibility genes for head and neck cancer but with a
      &gt; 80 pack year smoking history and no history of any cancer. Persons who meet these criteria
      are very rare in any population, but we have located 33 controls with these criteria.

      The cohort is not racially diversified, which enhances the opportunity for detecting
      relationships between genomic variation and disease and for discovering biomarker predictors
      of disease. Since 95% of the cohort is Whit-non-Hispanic, statistical power of genetic
      studies and precision of data analyses are improved by the lack of racial diversity of this
      cohort. Although the lack of generalizability to populations with other racial composition is
      certainly a limitation, the statistical associations found in this population can later be
      tested in other more racially diverse populations.

      The database is an excellent resource for developing methods for data mining, and the
      potential discovery of new statistical associations will lead to hypothesis generation. The
      extensive database for this longitudinal cohort provides rich opportunities for data mining,
      and for developing and testing new method of data mining.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 1990</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incident cancer during the period of cohort follow-up</measure>
    <time_frame>From enrollment to most recent encounter, average of 12 years, range of 1 day to 18 years</time_frame>
    <description>Using information from the medical examinations, medical history, assigned ICD codes and diagnosis verification with pathology reports, cancer outcomes are noted in the database with diagnosis date and method of diagnosis verification.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incident renal disease during the period of cohort follow-up</measure>
    <time_frame>From enrollment to most recent encounter, average of 12 years, range of 1 day to 18 years</time_frame>
    <description>Using information from the medical examinations, medical history, laboratory tests of blood serum and urine, and assigned ICD codes, persons with renal disease are noted in the database with diagnosis date and method of diagnosis verification.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Other incident conditions during the period of cohort followup</measure>
    <time_frame>From enrollment to most recent encounter, average of 12 years, range of 1 day to 18 years</time_frame>
    <description>Operational definition for diagnosis of medical condition determined by the research conducting the analyses. Operational definition my use information from the medical examinations, medical history, laboratory tests of blood serum and urine, and assigned ICD codes. Persons with that diagnosis are then are noted in the database with diagnosis date and method of diagnosis verification.</description>
  </other_outcome>
  <enrollment type="Actual">9782</enrollment>
  <condition>Cancer</condition>
  <condition>Renal Failure</condition>
  <condition>Diabetes</condition>
  <condition>Cardiovascular Disease</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      160,000 archived biosamples available, drawn from 1990-2008 (whole Bood, Plasma, Serum,
      Urine, Buffered Urine), extracted DNA. Breast, Renal &amp; Prostate cancer formalin fixed tissue.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Community members who lived or worked within the five mile radius of the Fernald Uranium
        Processing Plant boundary for a least 2 consecutive years between January 1, 1952 and
        December 18, 1984.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Lived or worked within five miles of the Feed Material Processing Center (FMPC) for 2
        consecutive years between January 1, 1952 and December 18, 1984. The Fernald Community
        Cohort (N=9782) includes 5294 female and 4489 male participants; 99.5% are Caucasian. The
        FMMP has conducted 42,775 medical examinations through the end of 2008.

        Exclusion Criteria:

        Worked at the Feeds Material Processing Center (FMPC)

        Employed by the US Department of Energy or National Lead of Ohio, Inc. (Plant Contractor)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan M Pinney, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://med.uc.edu/eh/research/projects/fcc</url>
    <description>website</description>
  </link>
  <results_reference>
    <citation>Wones R, Pinney SM, Buckholz JM, Deck-Tebbe C, Freyberg R, Pesce A. Medical monitoring: a beneficial remedy for residents living near an environmental hazard site. J Occup Environ Med. 2009 Dec;51(12):1374-83. doi: 10.1097/JOM.0b013e3181c558f1.</citation>
    <PMID>19952785</PMID>
  </results_reference>
  <results_reference>
    <citation>Blomkalns AL, Gavrila D, Thomas M, Neltner BS, Blanco VM, Benjamin SB, McCormick ML, Stoll LL, Denning GM, Collins SP, Qin Z, Daugherty A, Cassis LA, Thompson RW, Weiss RM, Lindower PD, Pinney SM, Chatterjee T, Weintraub NL. CD14 directs adventitial macrophage precursor recruitment: role in early abdominal aortic aneurysm formation. J Am Heart Assoc. 2013 Mar 8;2(2):e000065. doi: 10.1161/JAHA.112.000065.</citation>
    <PMID>23537804</PMID>
  </results_reference>
  <results_reference>
    <citation>You M, Wang D, Liu P, Vikis H, James M, Lu Y, Wang Y, Wang M, Chen Q, Jia D, Liu Y, Wen W, Yang P, Sun Z, Pinney SM, Zheng W, Shu XO, Long J, Gao YT, Xiang YB, Chow WH, Rothman N, Petersen GM, de Andrade M, Wu Y, Cunningham JM, Wiest JS, Fain PR, Schwartz AG, Girard L, Gazdar A, Gaba C, Rothschild H, Mandal D, Coons T, Lee J, Kupert E, Seminara D, Minna J, Bailey-Wilson JE, Amos CI, Anderson MW. Fine mapping of chromosome 6q23-25 region in familial lung cancer families reveals RGS17 as a likely candidate gene. Clin Cancer Res. 2009 Apr 15;15(8):2666-74. doi: 10.1158/1078-0432.CCR-08-2335. Epub 2009 Apr 7.</citation>
    <PMID>19351763</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu P, Vikis HG, Wang D, Lu Y, Wang Y, Schwartz AG, Pinney SM, Yang P, de Andrade M, Petersen GM, Wiest JS, Fain PR, Gazdar A, Gaba C, Rothschild H, Mandal D, Coons T, Lee J, Kupert E, Seminara D, Minna J, Bailey-Wilson JE, Wu X, Spitz MR, Eisen T, Houlston RS, Amos CI, Anderson MW, You M. Familial aggregation of common sequence variants on 15q24-25.1 in lung cancer. J Natl Cancer Inst. 2008 Sep 17;100(18):1326-30. doi: 10.1093/jnci/djn268. Epub 2008 Sep 9.</citation>
    <PMID>18780872</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu P, Yang P, Wu X, Vikis HG, Lu Y, Wang Y, Schwartz AG, Pinney SM, de Andrade M, Gazdar A, Gaba C, Mandal D, Lee J, Kupert E, Seminara D, Minna J, Bailey-Wilson JE, Spitz M, Amos CI, Anderson MW, You M. A second genetic variant on chromosome 15q24-25.1 associates with lung cancer. Cancer Res. 2010 Apr 15;70(8):3128-35. doi: 10.1158/0008-5472.CAN-09-3583.</citation>
    <PMID>20395203</PMID>
  </results_reference>
  <results_reference>
    <citation>Wagner SE, Burch JB, Bottai M, Pinney SM, Puett R, Porter D, Vena JE, HÃ©bert JR. Hypertension and hematologic parameters in a community near a uranium processing facility. Environ Res. 2010 Nov;110(8):786-97. doi: 10.1016/j.envres.2010.09.004.</citation>
    <PMID>20889151</PMID>
  </results_reference>
  <results_reference>
    <citation>Lu-Fritts PY, Kottyan LC, James JA, Xie C, Buckholz JM, Pinney SM, Harley JB. Association of systemic lupus erythematosus with uranium exposure in a community living near a uranium-processing plant: a nested case-control study. Arthritis Rheumatol. 2014 Nov;66(11):3105-12. doi: 10.1002/art.38786.</citation>
    <PMID>25103365</PMID>
  </results_reference>
  <results_reference>
    <citation>Fang S, Pinney SM, Bailey-Wilson JE, de Andrade MA, Li Y, Kupert E, You M, Schwartz AG, Yang P, Anderson MW, Amos CI. Ordered subset analysis identifies loci influencing lung cancer risk on chromosomes 6q and 12q. Cancer Epidemiol Biomarkers Prev. 2010 Dec;19(12):3157-66. doi: 10.1158/1055-9965.EPI-10-0792. Epub 2010 Oct 28.</citation>
    <PMID>21030603</PMID>
  </results_reference>
  <results_reference>
    <citation>Amos CI, Pinney SM, Li Y, Kupert E, Lee J, de Andrade MA, Yang P, Schwartz AG, Fain PR, Gazdar A, Minna J, Wiest JS, Zeng D, Rothschild H, Mandal D, You M, Coons T, Gaba C, Bailey-Wilson JE, Anderson MW. A susceptibility locus on chromosome 6q greatly increases lung cancer risk among light and never smokers. Cancer Res. 2010 Mar 15;70(6):2359-67. doi: 10.1158/0008-5472.CAN-09-3096. Epub 2010 Mar 9.</citation>
    <PMID>20215501</PMID>
  </results_reference>
  <results_reference>
    <citation>Yaghjyan L, Mahoney MC, Succop P, Wones R, Buckholz J, Pinney SM. Relationship between breast cancer risk factors and mammographic breast density in the Fernald Community Cohort. Br J Cancer. 2012 Feb 28;106(5):996-1003. doi: 10.1038/bjc.2012.1. Epub 2012 Jan 26.</citation>
    <PMID>22281662</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu P, Vikis HG, Lu Y, Wang Y, Schwartz AG, Pinney SM, Yang P, de Andrade M, Gazdar A, Gaba C, Mandal D, Lee J, Kupert E, Seminara D, Minna J, Bailey-Wilson JE, Amos CI, Anderson MW, You M. Cumulative effect of multiple loci on genetic susceptibility to familial lung cancer. Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):517-24. doi: 10.1158/1055-9965.EPI-09-0791.</citation>
    <PMID>20142248</PMID>
  </results_reference>
  <results_reference>
    <citation>Christiani DC. Lung cancer genetics: a family affair? Clin Cancer Res. 2009 Apr 15;15(8):2581-2. doi: 10.1158/1078-0432.CCR-09-0003. Epub 2009 Apr 7.</citation>
    <PMID>19351746</PMID>
  </results_reference>
  <results_reference>
    <citation>Xiong D, Wang Y, Kupert E, Simpson C, Pinney SM, Gaba CR, Mandal D, Schwartz AG, Yang P, de Andrade M, Pikielny C, Byun J, Li Y, Stambolian D, Spitz MR, Liu Y, Amos CI, Bailey-Wilson JE, Anderson M, You M. A recurrent mutation in PARK2 is associated with familial lung cancer. Am J Hum Genet. 2015 Feb 5;96(2):301-8. doi: 10.1016/j.ajhg.2014.12.016. Epub 2015 Jan 29.</citation>
    <PMID>25640678</PMID>
  </results_reference>
  <results_reference>
    <citation>Yang S, Pinney SM, Mallick P, Ho SM, Bracken B, Wu T. Impact of Oxidative Stress Biomarkers and Carboxymethyllysine (an Advanced Glycation End Product) on Prostate Cancer: A Prospective Study. Clin Genitourin Cancer. 2015 Oct;13(5):e347-51. doi: 10.1016/j.clgc.2015.04.004. Epub 2015 Apr 18.</citation>
    <PMID>25972296</PMID>
  </results_reference>
  <results_reference>
    <citation>Pinney SM, Biro FM. Letter to the editor re Morollo-Frosh &quot;Communicating results in post-Belmont era biomonitoring studies&quot;. Environ Res. 2015 Oct;142:756. doi: 10.1016/j.envres.2015.05.024. Epub 2015 Jun 12.</citation>
    <PMID>26076818</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu Y, Kheradmand F, Davis CF, Scheurer ME, Wheeler D, Tsavachidis S, Armstrong G, Simpson C, Mandal D, Kupert E, Anderson M, You M, Xiong D, Pikielny C, Schwartz AG, Bailey-Wilson J, Gaba C, De Andrade M, Yang P, Pinney SM; Genetic Epidemiology of Lung Cancer Consortium, Amos CI, Spitz MR. Focused Analysis of Exome Sequencing Data for Rare Germline Mutations in Familial and Sporadic Lung Cancer. J Thorac Oncol. 2016 Jan;11(1):52-61. doi: 10.1016/j.jtho.2015.09.015.</citation>
    <PMID>26762739</PMID>
  </results_reference>
  <results_reference>
    <citation>Martin AT, Pinney SM, Xie C, Herrick RL, Bai Y, Buckholz J, Martin VT. Headache Disorders May Be a Risk Factor for the Development of New Onset Hypothyroidism. Headache. 2017 Jan;57(1):21-30. doi: 10.1111/head.12943. Epub 2016 Sep 27.</citation>
    <PMID>27676320</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2014</study_first_submitted>
  <study_first_submitted_qc>November 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2014</study_first_posted>
  <last_update_submitted>January 27, 2017</last_update_submitted>
  <last_update_submitted_qc>January 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Susan Pinney</investigator_full_name>
    <investigator_title>Deputy director Center for Environmental Genetics, Department of Environmental Health, Program Leader, Cincinnati Cancer Center , UC College of Medicine</investigator_title>
  </responsible_party>
  <keyword>Cohort, Prospective, Biospecimens</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

